Development of novel benzomorpholine class of diacylglycerol acyltransferase i inhibitors

ACS Medicinal Chemistry Letters

Volumn 5, Issue 5, 2014, Pages 544-549

  Zhou, Gang ^a   Zorn, Nicolas ^a   Ting, Pauline ^a   Aslanian, Robert ^a   Lin, Mingxiang ^a   Cook, John ^a   Lachowicz, Jean ^a   Lin, Albert ^a   Smith, Michelle ^a   Hwa, Joyce ^a   Van Heek, Margaret ^a   Walker, Scott ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

benzomorpholine; DGAT1; diacylglycerol acyltransferase inhibitor; postprandial triglyceridemia (PPTG)

Indexed keywords

ACYLTRANSFERASE INHIBITOR; ANTIMETABOLITE; BENZOMORPHOLINE DERIVATIVE; DIACYLGLYCEROL ACYLTRANSFERASE 1; LIVER TRIACYLGLYCEROL LIPASE; MORPHOLINE DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CACO 2 CELL LINE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; EXPERIMENTAL DOG; EXPERIMENTAL MONKEY; EXPERIMENTAL OBESITY; FATTY LIVER; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RODENT MODEL; STRUCTURE ACTIVITY RELATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 84900426135     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400527n     Document Type: Article

References (21)

1. Semenkovich, C. F. Insulin resistance and atherosclerosis J. Clin. Invest. 2006, 116, 1813-1822
2. McGarry, J. D. Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes Diabetes 2002, 51 (1) 7-18
3. Shi, Y.; Burn, P. Lipid metabolic enzymes: emerging drug targets for treatment of obesity Nat. Rev. 2004, 3, 695-710
4. Zammit, V. A.; Buckett, L. K.; Turnbull, A. V.; Wure, J.; Proven, A. Diacylglycerol acyltransferases: Potential roles as pharmacological targets Pharmacol. Ther. 2008, 118, 295-302
5. Yen, C. E.; Stone, S. J.; Koliwad, D.; Harris, C.; Farese, R. V., Jr. DGAT enzymes and triacylglycerol biosynthesis J. Lipid Res. 2008, 49, 2283-2301
6. Chen, H. C.; Farese, R. V. DGAT and triglyceride synthesis: a new target for obesity treatment Trends Cardiovasc. Med. 2000, 10, 188-192
7. Cases, S.; Smith, S. J.; Zheng, Y-W; Myers, H. M.; Lear, S. R.; Sande, E.; Novak, S.; Collins, C.; Welch, C. B.; Lusis, A. J.; Erickson, S. K.; Farese, R. V., Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 13018-13023
8. Cases, S.; Stone, S. J.; Zhou, P.; Yen, E.; Tow, B.; Voelker, T.; Farese, R. V., Jr. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members J. Biol. Chem. 2001, 276, 38870-38876
9. Smith, S. J.; Cases, S.; Jensen, D. R.; Chen, H. C.; Sande, E.; Tow, B.; Sanan, D. A.; Raber, J.; Eckel, R. H.; Farese, R. V., Jr. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking DGAT Nat. Genet. 2000, 25, 87-90
10. Chen, H. C.; Jensen, D. R.; Myers, H. M.; Eckel, R. H.; Farese, R. V. Obesity resistance and enhanced glucose metabolism in mice transplanted with white adipose tissue lacking acyl CoA:diacylglycerol acyltransferase 1 J. Clin. Invest. 2003, 111 (11) 1715-1722
11. Chen, H. C.; Ladha, Z.; Smith, S. J.; Farese, R. V. Analysis of energy expenditure at different ambient temperatures in mice lacking DGAT1 Am. J. Physiol. Endocrinol. Metab. 2003, 284 (1) 213-218
12. Stone, S. J.; Myers, H. M.; Watkins, S. M.; Brown, B. E.; Feingold, K. R.; Elias, P. M.; Farese, R. V., Jr. Lipopenia and skin barrier abnormalities in DGAT2-deficient mice J. Biol. Chem. 2004, 279, 11767-11776
13. King, A. J.; Judd, A. S.; Souers, A. J. Inhibitors of diacylglycerol acyltransferase: a review of 2008 patents Expert Opin. Ther. Pat. 2010, 20, 19-29
14. Birch, A. M.; Bowker, S. S.; Butlin, R. J.; Donald, C. S.; McCoull, W.; Nowak, T.; Plowright, A. T. Oxadiazole derivatives as dgat inhibitors. Patent WO 2006/064189, 2006.
15. Fox, B. M.; Iio, K.; Li, K.; Choi, R.; Inaba, T.; Jackson, S.; Sagawa, S.; Shan, B.; Tanaka, M.; Yoshida, A.; Kayser, F. Discovery of pyrrolopyridazines as novel DGAT1 inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 6030-6033
16. Devita, R. J.; Pinto, S. Current Status of the Research and Development of Diacylglycerol O -Acyltransferase 1 (DGAT1) Inhibitors J. Med. Chem. 2013, 56, 9820-9825
17. Smith, R.; Campbell, A.-M.; Coish, P.; Dai, M.; Jenkins, S.; Lowe, D.; O'Connor, S.; Su, N.; Wang, G.; Zhang, M.; Zhu, L. Preparation of Benzazolylaminobiphenyloxoalkanoates for the Treatment of Obesity. US 2004/0224997, 2004.
18. Zhao, G.; Souers, A. J.; Voorbach, M.; Falls, H. D.; Droz, B.; Brodjian, S.; Lau, Y. Y.; Iyengar, R. R.; Gao, J.; Judd, A. S.; Wagaw, S. H.; Ravn, M. M.; Engstrom, K. M.; Lynch, J. K.; Mulhern, M. M.; Freeman, J.; Dayton, B. D.; Wang, X.; Grihalde, N.; Fry, D.; Beno, D. W. A.; Marsh, K. C.; Su, Z.; Diaz, G. J.; Collins, C. A.; Sham, H.; Reilly, R. M.; Brune, M. E.; Kym, P. R. Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor J. Med. Chem. 2008, 51, 380-383
19. Birch, A. M.; Birtles, S.; Buckett, L. K.; Kemmitt, P. D.; Smith, G. J.; Smith, T. J. D.; Turnbull, A. V.; Wang, S. J. Y. Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor J. Med. Chem. 2009, 52, 1558-1568
20. Lee, B.; Fast, A. M.; Zhu, J.; Cheng, J.; Buhman, K. K. Intestine specific expression of acyl CoA:diacylglycerol acyltransferase I reverses resistance to diet-induced hepatic steatosis and obesity in DGAT1-/- mice J. Lipid Res. 2010, 51, 1770-1780
21. Okawa, M.; Fujii, K.; Ohbuchi, K.; Okumoto, M.; Aragane, K.; Sato, H.; Tamai, Y.; Seo, T.; Itoh, Y.; Yoshimoto, R. Role of MGAT2 and DGAT1 in the release of gut peptides after triglyceride ingestion Biochem. Biophys. Res. Commun. 2009, 390, 377-381